Contact

Our portfolio

CRCbioscreen

Innovating colorectal cancer screening, CRCbioscreen develops stool-based tests to detect high-risk precursor lesions. Their research, led by experts from the Netherlands Cancer Institute and based on Amsterdam UMC technology, aims to improve early cancer detection. CRCbioscreen’s tests could potentially replace current national screening programs. The company is committed to advancing oncology diagnostics through innovative biomarker research.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Oncology
  • Founding year: 2021
Visit website

Want to get in contact about CRCbioscreen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Primagen
Investing in and developing molecular diagnostics for biotech innovation.
Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
Deep Sleep Technologies
Enhancing deep sleep through real-time, non-invasive brainwave stimulation using adaptive, science-backed algorithms.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Primagen
Investing in and developing molecular diagnostics for biotech innovation.
Regenesance
Engineering antibodies to treat neurodegenerative and immune diseases.
Deep Sleep Technologies
Enhancing deep sleep through real-time, non-invasive brainwave stimulation using adaptive, science-backed algorithms.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Explore full AAV portfolio
Contact